News &
Events

Bayer Pharmaceuticals will test new drugs using human heart tissues 3D-printed in Tel Aviv University

New drugs will be tested on 3-D printed human heart tissue
In the future: Bayer and TAU plan to screen drug candidates on 3D-printed whole human hearts

RAMOT@TAU is collaborating with Biological Industries Israel Beit Haemek Ltd. and the Israel Defense Forces (IDF) to detect antibodies and immune response to Coronavirus using a highly sensitive and specific serological assay developed at TAU

A TAU team led by Prof. Motti Gerlic and Prof. Ariel Munitz, both of TAU's Sackler Faculty of Medicine of Tel Aviv University, have developed a new test to add to the current diagnostic arsenal used to detect coronavirus infection. The unique test is serological — a blood test — and measures the presence of three type of antibodies against the virus.

RAMOT@TAU is collaborating with the Israel Defense Forces (IDF) to test thousands of soldiers using this test. In addition, a collaboration agreement was signed with Biological Industries Israel Beit Haemek on this assay.

NEOVII to Develop a Novel Vaccine for COVID-19 in an Exclusive Partnership With RAMOT@TAU

Neovii, the Swiss-based biopharmaceutical company and a member of Israeli-based Neopharm Group, has signed a research and license agreement with Tel Aviv University's (TAU) RAMOT, its technology transfer company, to work in collaboration with a team led by Professor Jonathan Gershoni of the School of Molecular Cell Biology and Biotechnology to develop a novel and potentially life-saving COVID-19 vaccine.

RAMOT@TAU Awarded U.S. Patent for Novel Coronavirus Vaccine Design

The patent covers a vaccine that targets the most vulnerable point in a coronavirus’s structure, through which it penetrates human cells. The patent has been submitted by Ramot, the technology transfer company of Tel-Aviv University and was granted in March by the U.S. patent and trademark office.